| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2018: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2017: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Outline of Final Research Achievements |
To clarify the pharmacotherapeutic role of the carnitine/organic cation transporter OCTN1, we examined intracellular mechanisms underlying neuronal differentiation and maturation promoted by OCTN1 and whether the in vivo substrate of OCTN1, ergothioneine (ERGO), is available as a biomarker for depression. OCTN1-mediated ERGO uptake promoted neuronal differentiation and maturation through the induction of neurotrophic factors and the activation of mechanistic target of rapamycin (mTOR) and tropomyosin receptor kinase B (TrkB) signaling. There was a positive correlation between the severity of depressive symptoms and ERGO concentration in the blood, suggesting that ERGO could be used as a biomarker for stress-induced neuropsychiatric disorders including depression.
|
